CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
|Articles|November 1, 2014
- BioPharm International-11-01-2014
- Volume 27
- Issue 11
Cell Culture Consumables Prevent Contamination
Eppendorf's Cell Culture Consumables have an ISO class/GMP class C clean room production standard.
Advertisement
Eppendorf’s Cell Culture Consumables have an ISO class/GMP class C clean room production standard and a sterility assurance level of 10-6.
The flasks feature air filter technology, with improved ergonomic design to increase handling efficiency. Each flask is given a 100% in-line pressure test for leaks. The resealable-top dishes include a corrugated ring to improve handling and transportation, with a SplashProtect ring inside the dish to protect against cross-contamination. The plates have been designed to minimize the “edge effect” with a chimney-well design in the outer moat of the 96-well plate.
Eppendorf
Articles in this issue
almost 12 years ago
Germany Post AMNOG: Insights for BioPharmaalmost 12 years ago
Standardizing Practices for Cellular Therapy Manufacturingalmost 12 years ago
Setting Standards for Biotech Therapeutics in Indiaalmost 12 years ago
Viral Clearance Challenges in Bioprocessingalmost 12 years ago
Outside Looking Inalmost 12 years ago
Hype vs. Healthalmost 12 years ago
New Era for Generic Drugsalmost 12 years ago
DoE Provides Benefits, but Preparation Is Necessaryalmost 12 years ago
Vector Manufacturing and Testing for Gene and Cell Therapy ApplicationsAdvertisement
Related to this article
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Advertisement
Advertisement